◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › R › RIGL

Rigel Pharmaceuticals Inc (RIGL) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-18

Rigel Pharmaceuticals Inc (RIGL) operates in the BIOTECHNOLOGY industry and is headquartered in South San Francisco, United States with about 172 employees. Its market capitalization is roughly $871 million. In the fiscal year ended 2025-12-31, RIGL reported $294M in revenue and $367M in net income.

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.

Interactive charts & full statements → Open the RIGL valuation workbench →

RIGL Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$277M	$294M	$179M	$117M	$120M	$149M	$109M	$59M	$45M	$4M	$20M	$29M	$8M	$7M	$2M	$5M	$125M	$1M	—	$13M	$33M
Gross Profit	$253M	$275M	$161M	$110M	$118M	$148M	$108M	$58M	$44M	($42M)	($43M)	($34M)	($59M)	($68M)	$2M	$5M	$125M	$1M	—	$13M	$33M
Gross Margin %	91.4%	93.3%	89.6%	93.9%	98.6%	99.3%	99.2%	98.5%	99.4%	-931.9%	-211.3%	-117.4%	-720.6%	-953.5%	100.0%	100.0%	100.0%	100.0%	—	100.0%	100.0%
Operating Income (EBIT)	$87M	$125M	$24M	($20M)	($56M)	($12M)	($29M)	($69M)	($73M)	($80M)	($70M)	($52M)	($91M)	($89M)	($99M)	($86M)	$35M	($112M)	($137M)	($80M)	($43M)
Operating Margin %	31.4%	42.6%	13.5%	-17.5%	-46.2%	-8.4%	-26.7%	-116.5%	-163.3%	-1775.6%	-342.1%	-179.1%	-1106.0%	-1251.3%	-4416.8%	-1818.3%	28.2%	-14938.3%	—	-631.2%	-128.6%
Net Income	$322M	$367M	$17M	($25M)	($59M)	($18M)	($30M)	($67M)	($70M)	($78M)	($69M)	($51M)	($91M)	($89M)	($99M)	($86M)	$38M	($112M)	($132M)	($74M)	($38M)
Net Margin %	116.3%	124.7%	9.8%	-21.5%	-48.7%	-12.0%	-27.4%	-112.2%	-158.3%	-1739.3%	-339.6%	-178.1%	-1101.9%	-1245.1%	-4392.9%	-1810.0%	30.3%	-14872.9%	—	-589.5%	-112.4%
EBITDA	$94M	$132M	$29M	($17M)	($54M)	($11M)	($28M)	($66M)	($72M)	($78M)	($63M)	($50M)	($89M)	($85M)	($97M)	($84M)	$39M	($110M)	($131M)	($80M)	($42M)
Earnings Per Share (EPS)	$17.01	$19.48	$0.99	$-1.44	$-3.40	$-1.05	$-1.76	$-3.98	$-4.39	$-6.17	$-7.33	$-5.82	$-10.37	$-10.20	$-6.14	$-3.67	$0.72	$-2.73	$-3.67	$-2.57	$-1.51
Shares Outstanding (M)	20M	19M	18M	17M	17M	17M	17M	17M	16M	13M	9M	9M	9M	9M	16M	23M	53M	41M	36M	29M	25M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RIGL Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$79M	$59M	$70M	$69M	$102M	$53M	$58M	$55M
Gross Profit	$70M	$54M	$64M	$65M	$97M	$49M	$52M	$47M
Gross Margin %	89.2%	92.2%	91.5%	93.2%	95.6%	91.7%	90.0%	85.5%
Operating Income (EBIT)	$24M	$12M	$23M	$28M	$61M	$13M	$17M	$14M
Operating Margin %	29.9%	20.2%	33.2%	40.9%	60.1%	23.9%	28.9%	25.4%
Net Income	$17M	$9M	$268M	$28M	$60M	$11M	$14M	$12M
Net Margin %	22.0%	14.7%	384.0%	40.2%	58.6%	21.5%	24.9%	22.5%
EBITDA	$25M	$14M	$25M	$30M	$62M	$14M	$18M	$15M
Earnings Per Share (EPS)	$0.88	$0.44	$14.23	$1.46	$3.28	$0.63	$0.80	$0.70
Shares Outstanding (M)	20M	20M	19M	19M	18M	18M	18M	18M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RIGL Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$79M	$76M	$31M	($6M)	($74M)	$6M	($52M)	($42M)	($59M)	($78M)	($76M)	($23M)	($70M)	($86M)	($85M)	($69M)	$47M	($103M)	($104M)	($52M)	($36M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$15M	$0M	$1M	$1M	$1M	$1M	$0M	$1M	$1M	$0M	$1M	$3M	$2M	$4M	$0M	$3M	$1M	$1M
Free Cash Flow (FCF)	$79M	$76M	$31M	($21M)	($74M)	$5M	($53M)	($43M)	($60M)	($78M)	($77M)	($24M)	($70M)	($87M)	($89M)	($72M)	$43M	($103M)	($106M)	($53M)	($37M)
FCF Margin %	28.7%	25.7%	17.3%	-17.8%	-61.7%	3.5%	-49.2%	-72.5%	-134.7%	-1733.3%	-376.3%	-82.9%	-850.5%	-1220.7%	-3936.4%	-1509.0%	34.5%	-13722.7%	—	-421.8%	-109.8%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RIGL Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$31M	$3M	$22M	$24M	$31M	($1M)	$15M	$22M
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	$31M	$3M	$22M	$24M	$31M	($1M)	$14M	$22M
FCF Margin %	39.0%	4.6%	31.5%	34.6%	30.0%	-1.7%	25.1%	39.2%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RIGL Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$521M	$514M	$164M	$117M	$134M	$167M	$110M	$148M	$139M	$119M	$78M	$132M	$154M	$226M	$310M	$257M	$187M	$141M	$144M	$116M	$113M
Cash & Cash Equivalents	$61M	$41M	$57M	$33M	$24M	$19M	$30M	$23M	$76M	$38M	$18M	$43M	$15M	$21M	$33M	$19M	$9M	$15M	$46M	$45M	$48M
Total Liabilities	$95M	$122M	$161M	$146M	$148M	$137M	$76M	$94M	$29M	$18M	$23M	$40M	$26M	$18M	$21M	$21M	$21M	$31M	$40M	$34M	$26M
Total Debt (Short + Long-Term)	$40M	$53M	$60M	$60M	$41M	$30M	$28M	$17M	$0M	$0M	$3M	$3M	$3M	$0M	$8M	$0M	$1M	$2M	$5M	$2M	$2M
Total Shareholders' Equity	$425M	$391M	$3M	($29M)	($14M)	$30M	$34M	$54M	$110M	$101M	$55M	$91M	$128M	$208M	$289M	$236M	$166M	$110M	$104M	$82M	$87M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RIGL viewer.

Other Companies in BIOTECHNOLOGY

IMMX · Immix Biopharma Inc — $894 million
FTH · Faeth Therapeutics, Inc. — $891 million
TBPH · Theravance Biopharma Inc — $884 million
ARDX · Ardelyx Inc — $883 million
OLMA · Olema Pharmaceuticals Inc — $859 million
WVE · Wave Life Sciences Ltd — $857 million
CADL · Candel Therapeutics Inc — $830 million
ACRS · Aclaris Therapeutics Inc — $818 million

← RIG All “R” companies RIGS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.